在生物制药领域，吉利德以其卓越的创新能力和市场领导力而备受瞩目。然而，近期的一系列事件却给这家行业巨头带来了不小的挑战，引发了业界的广泛关注与深入反思。近日，吉利德发布的2024年三季度财报引起关注。尽管整体营收达到75.15亿美元，同比增长7%，表现出稳健的态势，但吉利德肿瘤板块8.16亿美元的营收情况，却未能令投资者满意。该板块虽然同比增长6%，但环比却下降了近3%。对于在肿瘤领域投入巨资、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.